Not a single study
Story checked
STUDY: GLP-1 INJECTIONS MATCH SURGICAL WEIGHT LOSS OUTCOMES FOR BOWEL CONTROL RISKS - Siensmetrica (opens in a new tab)
siensmetrica.com · 2026-09-01
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
STUDY: GLP-1 INJECTIONS MATCH SURGICAL WEIGHT LOSS OUTCOMES FOR BOWEL CONTROL RISKS - Siensmetrica
siensmetrica.com · 2026-09-01
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedA comprehensive cohort study by Stanford Health Care researchers found no statistically significant difference in the risk of developing new-onset fecal incontinence between patients taking GLP-1 receptor agonists and those undergoing bariatric surgery.View evidenceHide evidence
As statedno statistically significant difference
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedThe researchers analyzed electronic health record data from more than 13,800 adults treated between 2015 and 2025 who had obesity and no prior history of bowel control issues.View evidenceHide evidence
As statedmore than 13,800 adults
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedThe study compared 12,284 patients who initiated GLP-1 medications such as semaglutide and tirzepatide with 1,540 patients who underwent bariatric surgery, including gastric bypass and sleeve gastrectomy.View evidenceHide evidence
As stated12,284 versus 1,540 patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedAfter propensity score matching, the article says fecal incontinence rates remained statistically non-significant at both the 1-year and 5-year follow-up marks.View evidenceHide evidence
As stated1-year and 5-year follow-up
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe article says GLP-1 patients had a higher average BMI at one year than the surgery group, but by year five the BMI difference narrowed and was no longer statistically significant.View evidenceHide evidence
As stated41.5 vs. 31.4 at one year
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
[A meta-analysis of efficacy and safety of anti-obesity medications in the treatment of childhood obesity].
Zhonghua Yi Xue Za Zhi · 2025 · PubMed
A278 GLP-1 Receptor Agonist Use for Weight Loss Management After Bariatric Surgery
Surgery for Obesity and Related Diseases · 2023 · Crossref
ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity in India - An Update (2025).
2025 · Europe PMC
Treatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach.
Clinical and Translational Gastroenterology · 2025 · PubMed
4152 PREOPERATIVE GLP-1 RECEPTOR AGONIST (GLP-1 RA) USE PREDICTS POSTOPERATIVE GLP-1 RA USE, BUT NOT GREATER PERCENT TOTAL WEIGHT LOSS (%TWL), 1-YEAR AFTER METABOLIC/BARIATRIC SURGERY (BMS)
Surgery for Obesity and Related Diseases · 2026 · Crossref
And 10 more candidates considered.